RECEIVE 25% OFF PUBLISHED ANTIBODIES WITH CODE "PUB25"! Offer valid for US customers and available internationally through distributors.

C12orf23 Polyclonal Antibody, RBITC Conjugated

Applications

  • IF(IHC-P)
  • IF(IHC-F)
  • IF(ICC)

Predicted Reactivity

  • Human
  • Mouse
  • Rat
  • Dog
  • Cow
  • Pig
  • Horse
  • Chicken
  • Rabbit
Overview
Catalog # bs-6987R-RBITC
Product Name C12orf23 Polyclonal Antibody, RBITC Conjugated
Applications IF(IHC-P), IF(IHC-F), IF(ICC)
Predicted Reactivity Human, Mouse, Rat, Dog, Cow, Pig, Horse, Chicken, Rabbit
Specifications
Conjugation RBITC
Host Rabbit
Source KLH conjugated synthetic peptide derived from human C12orf23
Clonality Polyclonal
Isotype IgG
Concentration 1ug/ul
Purification Purified by Protein A.
Storage Buffer Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Storage Condition Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
Target
Gene ID 90488
Subcellular location Cell membrane
Synonyms C12orf23; Chromosome 12 open reading frame 23; CL023_HUMAN; MGC17943; UPF0444 transmembrane protein C12orf23.
Background C12orf23 (chromosome 12 open reading frame 23), also known as FLJ11721, FLJ13959 or MGC17943, is a 116 amino acid multi-pass membrane protein belonging to the UPF0444 family. C12orf23 is encoded by a gene located on human chromosome 12, which encodes over 1,100 genes and comprises approximately 4.5% of the human genome. Chromosome 12 is associated with a number of skeletal deformities, including hypochondrogenesis, achondrogenesis and Kniest dysplasia. Noonan syndrome, which includes heart and facial developmental defects among the primary symptoms, is caused by a mutant form of PTPN11 gene product, SH-PTP2. Chromosome 12 is also home to a homeobox gene cluster which encodes crucial transcription factors for morphogenesis, and the natural killer complex gene cluster encoding C-type lectin proteins which mediate the NK cell response to MHC I interaction. Trisomy 12p leads to facial development defects, seizure disorders and a host of other symptoms varying in severity depending on the extent of mosaicism and is most severe in cases of complete trisomy.
Application Dilution
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200